BPA Call 36C24124A0014-36C24125N0296

Award Date 12/15/24
Potential Completion Date 12/14/25
Potential Value $270K
Ultimate Awardee
Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
West Haven, CT 06516, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award to Exosome Diagnostics Inc., a subsidiary of Bio-Techne Corporation, is for the delivery of 8 ProState Test IntelliScore Biopsies to the U.S. Department of Veterans Affairs (VA) VISN 2 network. The $17,284.96 firm fixed-price delivery order is placed under the Medical Laboratory Testing and Analysis Services GSA Schedule (FSS-621-II) contract and does not have a set-aside designation. Exosome Diagnostics, a for-profit organization specializing in advanced liquid...
This is a firm-fixed-price delivery order awarded by the Department of Veterans Affairs (VA) to Exosome Diagnostics Inc., a subsidiary of Bio-Techne Corporation, for the provision of the ExoDx Prostate (IntelliScore) test. The contract, valued at $521,554.88, is part of a larger $1,400,000 Federal Supply Schedule contract under GSA Schedule 621-II for Medical Laboratory Testing and Analysis Services, which enables various VA Veterans Integrated Service Networks (VISNs) to access Exosome...
This federal contract award was issued by the U.S. Department of Veterans Affairs (VA) to Exosome Diagnostics Inc., a for-profit organization that specializes in developing and commercializing advanced liquid biopsy diagnostic technologies for cancer detection and monitoring. The contract, valued at $69,891.36, is a Blanket Purchase Agreement (BPA) Call under the VA's Veterans Integrated Service Network (VISN) 1 and operates under the Medical Laboratory Testing and Analysis Services Federal...
This is a $692,149.52 firm-fixed-price delivery order contract awarded by the Veterans Integrated Service Network 6 (VISN 6) of the U.S. Department of Veterans Affairs (VA) to Exosome Diagnostics Inc., a subsidiary of Bio-Techne Corporation. The contract is for the provision of ExoDx Prostate (IntelliScore) testing services, a non-invasive liquid biopsy test that analyzes exosomal RNA biomarkers to assess the risk of clinically significant prostate cancer. The contract was awarded under the VA's...
This federal contract award is for the EXOSOME DX TESTING service provided by Exosome Diagnostics Inc., a subsidiary of Bio-Techne Corporation. The $37,576.00 firm-fixed-price delivery order was awarded by the Department of Veterans Affairs (VA) under the Medical Laboratory Testing and Analysis Services GSA Schedule contract. The contract supports the VA's prostate cancer screening initiatives for veterans, with Exosome Diagnostics supplying its ExoDx Prostate IntelliScore liquid biopsy test,...
This federal contract award is for the delivery of the ExoDx Prostate IntelliScore test by Exosome Diagnostics Inc., a subsidiary of Bio-Techne Corporation, to the Northport VA Medical Center. The contract, with a ceiling value of $375,760.00, has an ultimate completion date of September 30, 2029. It is a Delivery Order under the Medical Laboratory Testing and Analysis Services Federal Supply Schedule (FSS-621-II) contract, which is a multiple-award Indefinite Delivery Vehicle (IDV) managed by...
This is a $8,266.72 firm fixed price delivery order contract awarded to Exosome Diagnostics, Inc., a subsidiary of Bio-Techne Corporation, by the U.S. Department of Veterans Affairs (VA). The contract is for the provision of the ExoDx Prostate (IntelliScore) non-invasive, urine-based liquid biopsy test to support prostate cancer screening for veterans at the Northport VA Medical Center. This contract was awarded under the VA's Medical Laboratory Testing and Analysis Services Federal Supply...
This is a $9,018.24 firm fixed price purchase order awarded to Exosome Diagnostics Inc., a subsidiary of Bio-Techne Corporation, by the Department of Veterans Affairs (VA) Veterans Integrated Service Network 4 (VISN 4). The contract is for TESTING services, with a period of performance through December 11, 2024. There is no set-aside designation indicated. Exosome Diagnostics is a provider of liquid biopsy tests and laboratory services, primarily focused on non-invasive cancer detection and...
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 6 awarded Exosome Diagnostics Inc., a subsidiary of Bio-Techne Corporation, a $0.00 firm fixed price delivery order against the Medical Laboratory Testing and Analysis Services (FSS-621-II) GSA Schedule. The order is for EXO DX OPTION YR 1 services with a period of performance through September 30, 2022. No set-aside designation was used for this award. Exosome Diagnostics will provide...
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 6 awarded a $1,503.04 delivery order against the Medical Laboratory Testing and Analysis Services (FSS-621-II) multiple award schedule to Exosome Diagnostics Inc., a subsidiary of Bio-Techne Corporation. The firm fixed price order is for exosome diagnostic services to support the agency's medical testing programs. Performance will take place in Waltham, Massachusetts with a period of performance...

This federal contract award to Exosome Diagnostics Inc., a subsidiary of Bio-Techne Corporation, is for the provision of the company's ExoDx Prostate (IntelliScore) testing services. The $270,000.00 firm-fixed-price contract was awarded by the U.S. Department of Veterans Affairs (VA) Veterans Integrated Service Network (VISN) 1.

The contract, which runs through December 2025, is under the VA's Medical Laboratory Testing and Analysis Services GSA Schedule. It supports the VA's prostate cancer screening initiatives for veterans by providing non-invasive, urine-based liquid biopsy testing to assess the risk of clinically significant prostate cancer. Exosome Diagnostics has held multiple similar awards from various VA VISNs, including a $677,119.12 order from VISN 6 and a $371,250.88 contract with VISN 7, demonstrating the company's ongoing role in supplying innovative diagnostic services to federal healthcare programs. The contract has no set-aside designation.

Generated 12/18/24, 9:12 AM